Read: 103
ProPharma Receives Prestigious Awards in the 2024 Clinical Trials Excellence Recognition Program
September 24, 2024
We are honored to announce that ProPharma has been bestowed with dual accolades at the esteemed Clinical Trials Excellence Recognition Program for our contributions and achievements. We have been awarded in two categories: Business Expansion and Mergers Acquisitions.
The recognition highlights our strategic vision of integrating the acquisition of Clinres Farmacia into our organization, which has significantly amplified our global footprint and clinical capabilities. This achievement underlines our commitment to delivering innovative solutions that meet industry demands while expanding our reach across Central and Eastern Europe.
Jason DeGoes, President at ProPharma states: We are deeply honored to be acknowledged for leading in both Business Expansion and Mergers Acquisitions by the Clinical Trials Excellence Recognition Program. This achievement acknowledges our commitment towards providing exceptional services to clients worldwide. We are proud to incorporate Clinres Farmacia's expertise into our suite of services, thereby enhancing regulatory and clinical capabilities.
Our acquisition strategy has been pivotal in strengthening ProPharma’s global presence and capability set. The integration of Clinres Farmacia's experienced team with extensive regulatory knowledge complements the full spectrum of our service offerings.
Clinres Farmacia specializes in Regulatory Affrs, encompassing a range from marketing authorization applications to post-approval support procedures. This expertise is now integrated into ProPharma's portfolio, enhancing our ability to provide high-quality compliance services and ensure timely delivery.
ProPharma’s dedication towards innovation and healthier outcomes has been the driving force behind its acquisition strategy, including Clinres Farmacia. The combined expertise enables us to address a broader spectrum of client needs efficiently and effectively in pharmaceutical, medical device, and diagnostic development programs across Central and Eastern Europe.
We are immensely grateful for this recognition which reflects our relentless pursuit of excellence through strategic partnerships, added Jason DeGoes.
As we continue to expand our horizons globally, ProPharma remns committed to fostering a culture of innovation and striving towards healthier outcomes worldwide.
ProPharma has also been associated with several noteworthy acquisitions in recent years:
May 12, 2015 - ProPharma Group acquired Minnesota-based PROSAR, a comprehensive compliance services company serving the pharmaceutical, biotechnology, and medical device industries.
July 16, 2018 - The acquisition of Xo was announced by ProPharma Group. Based in the Netherlands, Xo is a leading life science services provider known for its expertise in clinical trials management.
October 6, 2021 - ProPharma Group acquired Pharmica Consulting, a life science company offering strategic guidance to organizations involved in pharmaceutical development and regulatory affrs.
ProPharma remns steadfast on our mission to provide top-tier compliance solutions across multiple sectors. Our commitment to innovation, growth, and community engagement continues to set us apart as an industry leader.
For more information or inquiries about our services and opportunities for collaboration, please visit the following links:
Contact Us
About Us
Our Process
Leadership
Global Footprint
Careers
RCO Solutions
This article is reproduced from: https://www.propharmagroup.com/press/propharma-honored-in-the-2024-clinical-trials-excellence-awards
Please indicate when reprinting from: https://www.o058.com/Pet_Hospital_Animal_Hospital/ProPharma_Excellence_Award_2024.html
ProPharma Clinical Trials Excellence Awards Global Expansion in Pharmaceutical Industry MergersAcquisitions in Healthcare Sector Clinres Farmacia Integration Success Story ProPharmas Strategic Vision Highlighted Enhanced Regulatory Services Worldwide